Therapeutic targeting of eukaryotic initiation factor (eIF) 4E.
cancer therapy
eIF4F
translational control
Journal
Biochemical Society transactions
ISSN: 1470-8752
Titre abrégé: Biochem Soc Trans
Pays: England
ID NLM: 7506897
Informations de publication
Date de publication:
27 02 2023
27 02 2023
Historique:
received:
06
12
2022
revised:
06
01
2023
accepted:
10
01
2023
pubmed:
21
1
2023
medline:
3
3
2023
entrez:
20
1
2023
Statut:
ppublish
Résumé
Fundamental studies unraveled the role of eukaryotic initiation factor (eIF) 4E in mRNA translation and its control. Under physiological conditions, regulation of translation by eIF4E is essential to cellular homeostasis. Under stress, gene flow information is parsed by eIF4E to support adaptive mechanisms that favor cell survival. Dysregulated eIF4E activity fuels tumor formation and progression and modulates response to therapy. Thus, there has been heightened interest in understanding eIF4E function in controlling gene expression as well as developing strategies to block its activity to treat disease.
Identifiants
pubmed: 36661272
pii: 232479
doi: 10.1042/BST20220285
doi:
Substances chimiques
Eukaryotic Initiation Factor-4E
0
Peptide Initiation Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-124Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2023 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.